NEW YORK--(BUSINESS WIRE)--
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will
release its financial results for the first quarter ended March 31,
2014, on Tuesday, May 13, 2014. Following the announcement, Ophthotech's
management will host a live conference call and webcast at 8:00 a.m.
Eastern Time to discuss Ophthotech's financial results for the first
quarter and provide a general business update.
To participate in this conference call, dial 888-438-5535 (USA) or
719-457-2727 (International), and enter passcode 7962682. A live,
listen-only audio webcast of the conference call can be accessed on the
Investor Relations section of the Ophthotech website at: www.ophthotech.com.
A replay will be available approximately two hours following the live
call for one week. The replay number will be 888-203-1112 (USA) or
719-457-0820 (International), passcode 7962682. A replay of the audio
webcast will be accessible at: www.ophthotech.com.
About Ophthotech Corporation
Ophthotech is a biopharmaceutical company specializing in the
development of novel therapeutics to treat diseases of the eye, with a
focus on developing innovative therapies for age-related macular
degeneration (AMD). Ophthotech's most advanced product candidate,
Fovista™ anti-PDGF therapy, is in Phase 3 clinical trials for use in
combination with anti-VEGF drugs for the treatment of wet AMD.
Ophthotech's second product candidate Zimura™, an inhibitor of
complement factor C5, is being developed for the treatment of dry and
wet forms of AMD. For more information, please visit www.ophthotech.com.
Any statements in this press release about Ophthotech's future
expectations, plans and prospects constitute forward-looking statements
for purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Any forward-looking statements represent
Ophthotech's views only as of the date of this press release. Ophthotech
anticipates that subsequent events and developments will cause its views
to change. While Ophthotech may elect to update these forward-looking
statements at some point in the future, Ophthotech specifically
disclaims any obligation to do so.
Source: Ophthotech Corporation